A paracrine role for il6 in prostate cancer patients: Lack of production by primary or metastatic tumor cells

Cancer Immunology Research

Volumn 3, Issue 10, 2015, Pages 1175-1184

  Yu, Shu Han ^a   Zheng, Qizhi ^a   Esopi, David ^b   Macgregor Das, Anne ^a   Luo, Jun ^a   Antonarakis, Emmanuel S ^b   Drake, Charles G ^a,b   Vessella, Robert ^c   Morrissey, Colm ^c   De Marzo, Angelo M ^a,b   Sfanos, Karen S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MACROPHAGE; METASTASIS; PARACRINE SIGNALING; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; CANCER STAGING; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GOLGI COMPLEX; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; REPRODUCIBILITY; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GOLGI APPARATUS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PARACRINE COMMUNICATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84962407508     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0013     Document Type: Article

References (35)

1. Keller ET, Wanagat J, Ershler WB. Molecular and cellular biology of Interleukin-6 and its receptor. Front Biosci 1996;1:d340-57.
2. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41:2502-12.
3. Drachenberg DE, Elgamal A-AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-33.
4. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-7.
5. Akimoto S, Okumura A, Fuse H. Relationship between serum levels of Interleukin-6, tumor necrosis factor-Alpha; and bone turnover markers in prostate cancer patients. Endocr J 1998;45:183-9.
6. Tumminello F, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol 2009;26:10-5.
7. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480. Clin Cancer Res 2005;11:1815-20.
8. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58:1008-15.
9. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-9.
10. Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007;69:113-7.
11. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
12. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159:2159-65.
13. Royuela M, Ricote M, Parsons MS, García-Tunon I, Paniagua R, De Miguel MP. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004;202:41-9.
14. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G, Klocker H, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191: 239-44.
15. Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, et al. The expression of osteoclastogenesis-Associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 2010;70:412-24.
16. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95:497-505.
17. Smith DA, Kiba A, Zong Y, Witte ON. Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues. Mol Cancer Res 2013; 11:1159-65.
18. Sung S-Y, Liao C-H, Wu H-P, Hsiao W-C, Wu IH, Jinpu, et al. Loss of Let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS ONE 2013;8:e71637.
19. Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, et al. Biobanking of derivatives from radical retropubic and robot-Assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate 2014;74:61-9.
20. Rhodes D, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
21. Player AN, Shen L-P, Kenny D, Antao VP, Kolberg JA. Single-copy gene detection using branched DNA (bDNA) in situ hybridization. JHistochem Cytochem 2001;49:603-11.
22. Tawara K, Oxford J, Jorcyk C. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011;3:177-89.
23. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159:197-207.
24. Smith PC, Hobisch A, Lin D-L, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001;12:33-40.
25. Ren C, Cheng X, Lu B, Yang G. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur J Cancer 2013;49:3889-99.
26. OguraH,MurakamiM,Okuyama Y, TsuruokaM, Kitabayashi C, Kanamoto M, et al. Interleukin-17 promotes autoimmunity by triggering a positivefeedback loop via interleukin-6 induction. Immunity 2008;29:628-36.
27. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7: 256-69.
28. Sfanos KS, DeMarzo AM. Prostate cancer and inflammation: The evidence. Histopathology 2012;60:199-215.
29. Sfanos KS, Wilson BA, De Marzo AM, Isaacs WB. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci U S A 2009;106: 3443-8.
30. Hoosein N, Abdul M, McCabe R, Gero E, Deftos L, Banks M, et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995;1:246-51.
31. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-[alpha] correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90:2312-6.
32. Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012;48:85-93.
33. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, et al. Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against Interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16:3028-34.
34. Singh VM, Salunga RC, Huang VJ, Tran Y, Erlander M, Plumlee P, et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol 2013;17:322-6.
35. Brown RSD, Edwards J, Bartlett JW, Jones C, Dogan A. Routine acid decalcification of bone marrow samples can preserve DNA for FISH and CGH studies in metastatic prostate cancer. J Histochem Cytochem 2002; 50:113-5.